| 000 | 01203 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250511185854.0 | ||
| 264 | 0 | _c19930222 | |
| 008 | 199302s 0 0 eng d | ||
| 022 | _a0093-7754 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan der Gaast, A | |
| 245 | 0 | 0 |
_aWhat is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days. _h[electronic resource] |
| 260 |
_bSeminars in oncology _cDec 1992 |
||
| 300 |
_a8-12 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xblood |
| 650 | 0 | 4 | _aRegression Analysis |
| 700 | 1 | _aVlastuin, M | |
| 700 | 1 | _aKok, T C | |
| 700 | 1 | _aSplinter, T A | |
| 773 | 0 |
_tSeminars in oncology _gvol. 19 _gno. 6 Suppl 14 _gp. 8-12 |
|
| 999 |
_c1495141 _d1495141 |
||